Changping District Emerges as a Hub for Oncology Vaccine R&D and Commercialization in Beijing

(Source: Qianlong Network)

Targeting the Goal of Conquering Cancer, Multiple Technical Routes in Changping DistrictZhongguancunLife Science Park accelerates progress, achieving significant therapeutic effects; among the seven companies in China that have been approved for investigational new drug applications for personalized tumor therapeutic vaccines, three are located in Changping District, with related products already entering the registered clinical stage… Changping District is becoming a highland for the research, development, and transformation of personalized tumor therapeutic vaccines in China.

The mRNA (messenger ribonucleic acid) personalized tumor neoantigen vaccine developed by NeoCura, which originates from Changping District, is currently undergoing Phase I clinical trials at Peking Union Medical College Hospital and Beijing Cancer Hospital.

"In the past, we often referred to the 'three main methods' of cancer treatment: radiotherapy, chemotherapy, and surgery. Immunotherapy, however, is a new approach. Tumor neoantigens are specifically expressed on tumor cells, helping the immune system precisely target, attack, and destroy them," said Li Wei, Executive Vice President of NeoCura Bio-Medical Technology Co., Ltd. This tumor vaccine is expected to achieve targeted therapy, avoiding the dilemma of conventional radiotherapy and chemotherapy where 'killing a thousand enemies but losing eight hundred of our own.'

The cell and gene therapy (CGT) industry, including tumor vaccines, is a typical representative of future industries and has become an industry consensus. However, to date, no tumor vaccine product has been approved for marketing globally. Changping District is targeting the window period, with Life Science Park at its core, accelerating the development of therapeutic cancer vaccines through three technical routes: DC cell (dendritic cell) vaccines, mRNA vaccines, and peptide vaccines. More encouragingly, their "performance" in clinical trials can be described as outstanding.

"The development of pharmaceutical enterprises ultimately relies on the support of the entire healthcare system. From this perspective, Beijing has an absolute advantage. Establishing our company in Changping District allows us to fully utilize the rich and high-quality medical resources," said Li Wei. "Without leaving Beijing, we can find suitable large hospitals and companies to collaborate on cancer vaccine research and development. These advantages will undoubtedly promote clinical trials to be carried out better and faster."

This company is just one representative example, as the Life Science Park has successfully transformed nearly 50 high-quality CGT projects. Among them, more than 30 projects have received clinical trial approvals, and over 10 additional projects are awaiting submission for clinical trial registration. The number of technology routes under research has exceeded 190, and the industrial cluster is taking shape.

In the future, the park will further increase the supply of industrial space and build a CGT public preparation service platform in the Beijing area.

Changping District introduced that it will reduce the compliance risks of innovative pharmaceutical companies, shorten the R&D and review cycles, and create a full-chain collaborative development environment for enterprises by establishing normalized communication with regulatory authorities, striving to push for the approval and market launch of 3 CGT new drugs within 3 years.